Leerink Partnrs Issues Positive Forecast for IRWD Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Stock analysts at Leerink Partnrs lifted their Q2 2025 earnings per share (EPS) estimates for shares of Ironwood Pharmaceuticals in a research report issued to clients and investors on Monday, April 14th. Leerink Partnrs analyst F. Khurshid now expects that the biotechnology company will post earnings of $0.01 per share for the quarter, up from their previous forecast of ($0.02). The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $0.10 per share. Leerink Partnrs also issued estimates for Ironwood Pharmaceuticals' Q4 2025 earnings at $0.14 EPS, FY2025 earnings at $0.24 EPS and FY2026 earnings at $0.48 EPS.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.08). The company had revenue of $90.55 million during the quarter, compared to analyst estimates of $93.85 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%.

Other analysts also recently issued research reports about the stock. Wells Fargo & Company reissued an "equal weight" rating and set a $1.00 target price (down previously from $7.00) on shares of Ironwood Pharmaceuticals in a research report on Tuesday, April 15th. Leerink Partners cut their target price on shares of Ironwood Pharmaceuticals from $3.00 to $1.00 and set a "market perform" rating on the stock in a research note on Monday, April 14th. StockNews.com cut shares of Ironwood Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Tuesday, April 15th. Jefferies Financial Group reissued a "hold" rating and issued a $0.70 price objective (down from $8.00) on shares of Ironwood Pharmaceuticals in a research report on Tuesday, April 15th. Finally, Craig Hallum downgraded Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 16th. Eight equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $4.78.

Ironwood Pharmaceuticals Price Performance

IRWD stock traded down $0.01 during trading on Thursday, reaching $0.70. 830,056 shares of the stock traded hands, compared to its average volume of 2,554,042. The business's 50 day moving average price is $1.41 and its 200-day moving average price is $2.98. The firm has a market capitalization of $112.94 million, a PE ratio of -23.27 and a beta of 0.30. Ironwood Pharmaceuticals has a 52-week low of $0.59 and a 52-week high of $8.45.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of IRWD. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Ironwood Pharmaceuticals in the fourth quarter worth approximately $36,000. Journey Strategic Wealth LLC purchased a new position in Ironwood Pharmaceuticals during the 4th quarter worth approximately $45,000. Catalyst Funds Management Pty Ltd purchased a new position in Ironwood Pharmaceuticals during the 4th quarter worth approximately $47,000. Envestnet Asset Management Inc. acquired a new stake in Ironwood Pharmaceuticals during the 4th quarter valued at $50,000. Finally, Xponance Inc. purchased a new stake in shares of Ironwood Pharmaceuticals in the fourth quarter valued at $50,000.

Insider Activity

In other Ironwood Pharmaceuticals news, CMO Michael Shetzline sold 41,269 shares of the company's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $72,633.44. Following the completion of the sale, the chief marketing officer now directly owns 554,007 shares of the company's stock, valued at approximately $975,052.32. This represents a 6.93 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Thomas A. Mccourt sold 139,064 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $1.76, for a total transaction of $244,752.64. Following the completion of the transaction, the chief executive officer now directly owns 1,160,634 shares in the company, valued at $2,042,715.84. This represents a 10.70 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 192,381 shares of company stock worth $338,591. 12.90% of the stock is owned by company insiders.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.